
Program:
Start Year:
2019
Why did you choose Duke for your residency training?
I completed an away rotation as a fourth year medical student on Duke's Gynecologic Oncology service and had an incredible experience. I instantly felt like a part of the Duke family and knew I wanted to come back for residency. Duke offers exceptional training and opportunities for residents while upholding a supportive environment. The residents and faculty serve as leaders and encourage each other to work at the highest standards in order to provide the best care for patients.
What excites you about the residency program at Duke OB/GYN?
Duke OB/GYN is a strong academic program which emphasizes quality patient care, medical education, research and advocacy for women's health. I am excited to learn from the exceptional residents and attendings at Duke and develop into the best OB/GYN I can be for future patients.
What are your career goals?
I hope to subspecialize in Gynecologic Oncology and aid in the evaluation and treatment of women with cancer. I hope to continue investigating gynecologic malignancies and therapeutic agents in order to best serve this patient population.
What are your hobbies?
I love spending time with my family, being outdoors and going on hikes, and exploring Durham!
Education & Training
Undergraduate school & graduation year:
Samford University, 2015
Medical school & graduation year:
University of South Carolina School of Medicine Greenville, 2019
Awards and Honors
2021 Appleseed Resident Teaching Award
Alpha Omega Alpha Honor Medical Society
Christopher Michael McManus Memorial Scholarship
Publications
Montes de Oca MK, Dotters-Katz S, Kuller J, Previs RA. Adnexal masses in pregnancy. (Accepted in Obstetrical and Gynecological Survey, July 2021 Issue)
Watson C, Broadwater G, Wong J, Spinosa D, Montes de Oca MK, Datto M, Green M, Hubbard C, McKinney M, McCall S, Havrilesky L, Strickler J, Berchuck A, Strickland K, Previs R. Results and clinical utilization of foundation medicine molecular tumor profiling in uterine and ovarian cancers. Targeted Oncology 2021; 16: 109-118.
Montes de Oca MK, Pearlman RL, McClees SF, Strickland R, Afaq F. Phytochemicals for the prevention of photocarcinogenesis. Photochem Photobiol 2017; 93(4):956-974.
Pearlman RL, Montes de Oca MK, Pal HC and Afaq F. Potential therapeutic targets of epithelial‐mesenchymal transition in melanoma. Cancer Lett 2017; 391:125-140.
Montes de Oca MK, Nye A, Porter C, Collins J, Satterfield C, Schammel CMG, Trocha SD. Head and Neck Cancer PEG Site Metastases—Case Report, Meta-analysis and Literature Review. Head & Neck. 2019;1-9.
Nye A, Collins JD, Porter CL, Montes de Oca MK, George K, Stafford CG, Schammel C, Horton S, Trocha SD. Predictive Genetic Profiles for Regional Lymph Node Metastasis in Primary Cutaneous Melanoma: A Case Matched Pilot Study. 2018.Melanoma Research. 2018; 28(6):555-561.
Montes de Oca MK, Osborne Z, Fabiano S. (2019, August 13). Jackhammer Dissection. EM Resident, 46(4), 23-24.
Sharma P, Montes de Oca MK, Alkeswani AR, et al. Tea polyphenols for the prevention of UVB-induced skin cancer. Photodermatol Photoimmunol Photomed 2018; 34:50-59.
Montes de Oca MK, Jamison RA. Pancreatic panniculitis as the initial presentation of intrahepatic cholangiocarcinoma. Journal of the American Academy of Dermatology Case Reports 2018; 4(6):528-530.
Montes de Oca MK. Medical error disclosure: A professional and ethical obligation. The Linacre Quarterly 2018; 85(3); 293-298.
Montes de Oca, MK. Contributing Author In: Le T, Bhushan V, Sochat M, et al. First Aid for the USMLE Step 1, 30th ed. New York: McGraw-Hill, 2020.
Presentations
Reid H, Montes de Oca MK, Fayanju O, Havrilesky L, Davidson B. (2021). 92741 Racial differences in patient reported distress among women with endometrial cancer. Journal of Clinical and Translational Science, 5(S1), 86-87.
Montes de Oca MK, Albright B, Havrilesky L, Moss H. (2021, April). The subjective interpretation of negative trial results during oral plenary presentations. In European Journal of Gynaecological Oncology (Vol. 42, No. 2, pp. 390-390).
Montes de Oca MK, Albright B, Havrilesky L, Moss H. Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial adenocarcinoma. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer. (March 19-21, 2021).
Montes de Oca MK, Reid H, Davidson B. Cytoreduction status and platinum sensitivity in women with recurrent ovarian cancer. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer. (March 19-21, 2021).
Montes de Oca MK, Spinosa D, Howell E, Knockenhauer H, Watson C, Weber J, Truong T, Previs R. Gynecologic oncologists: surgeons and oncologists? Evaluating the clinical trial landscape by intervention type. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer. (March 19-21, 2021).
Montes de Oca MK, Reid H, Spinosa D, Watson C, McNally L. Perioperative risk stratification using the timed up and go test. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer. (March 19-21, 2021).
Montes de Oca MK, Albright B, Havrilesky L, Moss H. The subjective interpretation of negative trial results during oral plenary presentations. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer. (March 19-21, 2021).
Spinosa D, Howell E, Montes de Oca MK, Knockenhauer H, Watson C, Weber J, Truong T, Previs R. Diversity and transparency in gynecologic oncology clinical trials. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer. (March 19-21, 2021).
Spinosa D, Howell E, Montes de Oca MK, Knockenhauer H, Watson C, Weber J, Truong T, Previs R. Gynecologic oncology clinical trials: Study the studies to terminate the terminations. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer. (March 19-21, 2021).
Reid H, Montes de Oca MK, Fayanju O, Havrilesky L, Davidson B. Racial differences in patient-reported distress among women with endometrial cancer. Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer. (March 19-21, 2021).